Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results

MLA

Francois Wilhelm, et al. “Therapy of Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (MTNBC) with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate (ADC), Sacituzumab Govitecan (IMMU-132): Phase II Results.” Journal of Clinical Oncology, vol. 34, June 2016, p. LBA509. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....76e396cfcc69034636966f03718f8ac5&authtype=sso&custid=ns315887.

APA

Francois Wilhelm, Vandana G. Abramson, Aditya Bardia, Kevin Kalinsky, Linda T. Vahdat, RL Moroose, Steven J. Isakoff, Ingrid A. Mayer, Jennifer R. Diamond, Dejan Juric, Jordan Berlin, Alexander Starodub, Nikita C. Shah, Wells A. Messersmith, Allyson J. Ocean, David M. Goldenberg, Joyce O’Shaughnessy, Robert M. Sharkey, Michael J. Guarino, & Geoffrey I. Shapiro. (2016). Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. Journal of Clinical Oncology, 34, LBA509.

Chicago

Francois Wilhelm, Vandana G. Abramson, Aditya Bardia, Kevin Kalinsky, Linda T. Vahdat, RL Moroose, Steven J. Isakoff, et al. 2016. “Therapy of Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (MTNBC) with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate (ADC), Sacituzumab Govitecan (IMMU-132): Phase II Results.” Journal of Clinical Oncology 34 (June): LBA509. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....76e396cfcc69034636966f03718f8ac5&authtype=sso&custid=ns315887.